天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 16091-26-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 16091-26-2
Chemical Structure| 16091-26-2
Structure of 16091-26-2 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 16091-26-2 ]

Related Doc. of [ 16091-26-2 ]

Alternatived Products of [ 16091-26-2 ]
Product Citations

Product Details of [ 16091-26-2 ]

CAS No. :16091-26-2 MDL No. :MFCD00071750
Formula : C13H12N2O Boiling Point : -
Linear Structure Formula :- InChI Key :IRFCTHNJIWUUJZ-UHFFFAOYSA-N
M.W : 212.25 Pubchem ID :72896
Synonyms :
Chemical Name :3'-Aminobenzanilide

Calculated chemistry of [ 16091-26-2 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.0
Num. rotatable bonds : 3
Num. H-bond acceptors : 1.0
Num. H-bond donors : 2.0
Molar Refractivity : 65.06
TPSA : 55.12 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.22 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.76
Log Po/w (XLOGP3) : 1.94
Log Po/w (WLOGP) : 2.34
Log Po/w (MLOGP) : 2.4
Log Po/w (SILICOS-IT) : 1.87
Consensus Log Po/w : 2.06

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.74
Solubility : 0.391 mg/ml ; 0.00184 mol/l
Class : Soluble
Log S (Ali) : -2.72
Solubility : 0.403 mg/ml ; 0.0019 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.56
Solubility : 0.00582 mg/ml ; 0.0000274 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.47

Safety of [ 16091-26-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 16091-26-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 16091-26-2 ]

[ 16091-26-2 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 4771-08-8 ]
  • [ 16091-26-2 ]
YieldReaction ConditionsOperation in experiment
89.8% With iron; ammonium chloride In ethanol; water for 2 h; Reflux Compound 10a was dissolved in EtOH (20 ml), and an aqueous solution of iron powder (2.5 g) and ammonium chloride (0.53 g, 10 mmol) was added and the reaction was refluxed for 2 hours. Followed by hot filter, collected filtrate spin dry. The solid was dissolved in acetone and the filtrate was collected by filtration and the solution was spin-dried to give compound 11a in 89.8percent yield.
Reference: [1] Synthesis (Germany), 2012, vol. 44, # 16, p. 2579 - 2586
[2] Synthetic Communications, 2000, vol. 30, # 20, p. 3639 - 3644
[3] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2000, vol. 39, # 9, p. 709 - 711
[4] Patent: CN106699755, 2017, A, . Location in patent: Paragraph 0103; 0195; 0196
[5] Journal of Chemical Research, 2006, # 4, p. 223 - 224
[6] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 9, p. 3088 - 3115
[7] Chemische Berichte, 1902, vol. 35, p. 3330
[8] Chemische Berichte, 1874, vol. 7, p. 498
[9] Helvetica Chimica Acta, 1937, vol. 20, p. 691,699
[10] Journal fuer Praktische Chemie (Leipzig), 1986, vol. 328, # 4, p. 497 - 514
[11] Journal of Medicinal Chemistry, 1986, vol. 29, # 3, p. 417 - 423
[12] Arzneimittel-Forschung/Drug Research, 1999, vol. 49, # 2, p. 81 - 87
[13] Chemical Communications, 2005, # 43, p. 5438 - 5440
[14] Journal of Organic Chemistry, 2009, vol. 74, # 11, p. 4272 - 4277
[15] Journal of Medicinal Chemistry, 2012, vol. 55, # 4, p. 1559 - 1571
[16] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 16, p. 3968 - 3973
[17] European Journal of Medicinal Chemistry, 2017, vol. 136, p. 372 - 381
  • 2
  • [ 55-21-0 ]
  • [ 591-19-5 ]
  • [ 16091-26-2 ]
YieldReaction ConditionsOperation in experiment
92% With copper(l) iodide; dimethylaminoacetic acid; potassium carbonate In N,N-dimethyl-formamide at 100℃; for 24 h; Schlenk technique; Inert atmosphere General procedure: A Schlenk tube was charged with amide (1.2 mmol), aryl halide (1 mmol), CuI (0.05 or 0.1 mmol), N,N-dimethylglycine (0.1 or 0.2 mmol), and potassium carbonate (2 mmol). The tube was evacuated and backfilled with argon at room temperature. DMF (0.5 mL) was added under argon via syringe. The Schlenk tube was immersed in a preheated oil bath and the reaction mixture was stirred for the specified time at the indicated temperature. The cooled mixture was partitioned between water and ethyl acetate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate.The combined organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluting with 1:8 to 1:2 ethyl acetate/petroleum ether) to give the the desired N-aryl amides.
Reference: [1] Molecules, 2014, vol. 19, # 9, p. 13448 - 13460
  • 3
  • [ 108-45-2 ]
  • [ 98-88-4 ]
  • [ 16091-26-2 ]
Reference: [1] Journal of Organic Chemistry USSR (English Translation), 1981, vol. 17, # 11, p. 2139 - 2141[2] Zhurnal Organicheskoi Khimii, 1981, vol. 17, # 11, p. 2394 - 2396
[3] Patent: US2013/48911, 2013, A1, . Location in patent: Paragraph 0071; 0072
[4] Journal of the American Society for Mass Spectrometry, 2016, vol. 27, # 5, p. 917 - 926
  • 4
  • [ 98-88-4 ]
  • [ 16091-26-2 ]
Reference: [1] Synthesis (Germany), 2012, vol. 44, # 16, p. 2579 - 2586
[2] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 16, p. 3968 - 3973
[3] European Journal of Medicinal Chemistry, 2017, vol. 136, p. 372 - 381
[4] Patent: WO2017/98421, 2017, A1,
  • 5
  • [ 65-85-0 ]
  • [ 16091-26-2 ]
Reference: [1] European Journal of Medicinal Chemistry, 2017, vol. 136, p. 372 - 381
[2] Patent: CN106699755, 2017, A,
  • 6
  • [ 99-09-2 ]
  • [ 16091-26-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 16, p. 3968 - 3973
  • 7
  • [ 68621-88-5 ]
  • [ 16091-26-2 ]
Reference: [1] Patent: WO2017/98421, 2017, A1,
  • 8
  • [ 6540-25-6 ]
  • [ 16091-26-2 ]
Reference: [1] Patent: CN106699755, 2017, A,
  • 9
  • [ 1576-38-1 ]
  • [ 16091-26-2 ]
Reference: [1] Journal of Organic Chemistry, 2017, vol. 82, # 24, p. 13423 - 13439
  • 10
  • [ 6380-07-0 ]
  • [ 16091-26-2 ]
Reference: [1] Journal of Organic Chemistry, 2017, vol. 82, # 24, p. 13423 - 13439
  • 11
  • [ 68621-88-5 ]
  • [ 98-88-4 ]
  • [ 16091-26-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 10, p. 4337 - 4350
Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;